FDA proposes QbD methods for skin patches

In recently issued draft guidance, the FDA advocates Quality by Design principles in the manufacture and development of skin-patch drugs. The document covers transdermal and transmucosal drug delivery systems as well as topical patch products.

The guidance addresses an FDA finding that 10 to 95 percent of the drug remains on the patch after use, posing risks to both patients and those around them.

"We recommend that an enhanced design and development approach--specifically Quality by Design (QbD), as described in the International Conference on Harmonization (ICH) guidance for industry Q8(R2) Pharmaceutical Development--be used," according to the document. "The application of QbD, including product monitoring, can lead to continual improvement of the product throughout its lifecycle."

- here's the draft guidance


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.